Jazz Pharmaceuticals JAZZ Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
Cash equivalents and investments are considered available-for-sale securities. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the condensed consolidated statements of income (loss). Our investment balances represent time deposits with original maturities of greater than three months and less than one year. Interest income from available-for-sale securities was $23.4 million and $27.6 million in the three months ended March 31, 2026 and 2025, respectively.
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's interest income?
- Jazz Pharmaceuticals (JAZZ) reported interest income of $23.4M in Q1 2026.
- How has Jazz Pharmaceuticals's interest income changed year-over-year?
- Jazz Pharmaceuticals's interest income decreased by 15.2% year-over-year, from $27.6M to $23.4M.
- What is the long-term trend for Jazz Pharmaceuticals's interest income?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's interest income has grown at a 162.8% compound annual growth rate (CAGR), from $1.8M to $85.8M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Jazz Pharmaceuticals's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
